glp 1 cardiovascular risk reduction GLP-1 Receptor Agonists for the of Atherosclerotic in Patients With Type 2 Diabetes GLP-1 drugs improve liver and

Mechanistic hypotheses include reduced leptin-driven T-helper (Th)1/Th17 activity, improved adipokine balance, and modulation of gut-thyroid axis pathways

A major new clinical trial is putting a spotlight on one of the biggest conversations in medicine right now: what happens when GLP-1based therapy is brought into psoriatic arthritis care

Find out if LifeMD Medical Weight Program can help with weight loss, appetite control, and metabolism boost in our comprehensive 2026 review.

Today, Gubra A/S (Company), a company specializing in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, announced a collaboration with Amylyx Pharmaceuticals, Inc